Primary Central Nervous System Lymphoma
What's New
Last Posted: Sep 11, 2024
- Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.
Zhiyong Zeng, et al. Signal transduction and targeted therapy 2024 0 (1) 229 - Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
Palada Pitakkitnukun, et al. Scientific reports 2024 0 (1) 9695 - Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
Zhang Rui, et al. Clinical lymphoma, myeloma & leukemia 2023 0 - Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
Hattori Keiichiro, et al. Cancer science 2017 0 (1) 225-230 - Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
Wang Yucai, et al. Blood cancer journal 2019 0 (9) 73 - Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.
Sethi Tarsheen K, et al. Leukemia & lymphoma 2019 0 (12) 2880-2889 - MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.
Nayyar Naema, et al. Blood advances 2019 0 (3) 375-383 - Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen Manuel, et al. The Journal of molecular diagnostics : JMD 2020 0 (10) 1300-1307 - Primary CNS lymphoma commonly expresses immune response biomarkers.
Ou Alexander, et al. Neuro-oncology advances 2020 0 (1) vdaa018 - Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.
Yoon Sang Eun, et al. Cancer research and treatment 2021 0 (2) 597-612
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: